Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyâ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-03	$1.660	-0.60%	2,060
26-09-02	$1.670	+0.60%	8,501
26-09-01	$1.660	-2.35%	6,369
26-08-31	$1.700	+5.92%	13,211
26-08-28	$1.605	-3.31%	35,678

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq 10:23:05 2026-09-03 am EDT			5-day change	1st Jan Change
1.660 ^USD	-0.60%		0.00%	-48.61%

Aug. 14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jun. 29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI

Market Cap	4.24M 3.65M 3.43M 3.13M 5.85M 401M 5.9M 40.52M 15.78M 205M 15.93M 15.58M 660M	P/E 2024	-0.65x	P/E 2025	-1.47x
Enterprise Value	2.86M 2.46M 2.31M 2.11M 3.94M 270M 3.97M 27.29M 10.63M 138M 10.73M 10.5M 445M	EV / Sales 2024	195,938,500x	EV / Sales 2025	1,164,761,400x
Free-Float	84.7%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	TCRT	Delayed
CBOE	TCRT	Real-time

Aug. 14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jun. 29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI
May. 26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI
May. 18	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models	RE
May. 18	Alaunos Therapeutics Announces Updated Preclinical Data For ALN1003	CI
May. 15	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 30	Alaunos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 05	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
Mar. 02	Alaunos Therapeutics, Inc. Announces Early Data from Two Non-Good Laboratory Practice Diet-Induced Obesity Mouse Studies Evaluating ALN1003	CI
Mar. 02	Alaunos Therapeutics announces positive preclinical proof-of-concept data for ALN1003, a differentiated non-hormonal oral treatment for obesity and related metabolic disorders	RE
Feb. 24	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
Jan. 08	Alaunos Therapeutics terminates engagement with Cantor Fitzgerald	RE

Alaunos Therapeutics, Inc. Stock

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Valuation : Alaunos Therapeutics, Inc.

Chart: Alaunos Therapeutics, Inc.

Latest news : Alaunos Therapeutics, Inc.

Analysts' recommendations : Alaunos Therapeutics, Inc.

Press Releases : Alaunos Therapeutics, Inc.

News in other languages : Alaunos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Alaunos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

23-08-16	HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	MT
23-08-15	Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	MT
22-10-04	Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-07-15	Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-05-04	Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	MT

Aug. 14	Ziopharm: Q2 Earnings Snapshot	AQ
Jun. 29	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
May. 26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
May. 18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ
May. 15	Ziopharm: Q1 Earnings Snapshot	AQ

15-06-30	Alibaba : Les valeurs à suivre sur les marchés américains
15-06-30	USA-Les valeurs à suivre à Wall Street

Current month	-2.35%
1 month	-12.86%
3 months	-36.64%
6 months	-50.45%
Current year	-48.61%

1 week	1.55	1.73
1 month	1.55	2.05
Current year	1.55	4.04
1 year	1.55	4.59
3 years	1.31	32.85
5 years	1.31	601.5
10 years	1.31	1,182

Manager	Title	Age	Since
Holger Weis CEO	Chief Executive Officer	63	2025-07-01
Ferdinand Groenewald DFI	Director of Finance/CFO	42	2025-02-21

Director	Title	Age	Since
Jaime Vieser BRD	Director/Board Member	56	2020-12-15
Holger Weis CHM	Chairman	63	2023-09-21
Robert Postma BRD	Director/Board Member	72	2021-02-04

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/6/26	Holger Weis	Free	Chief Executive Officer	4,363	0.1787%
7/23/26	Michael Jerman	Free	Director	8,138	0.3332%
7/23/26	Holger Weis	Free	Chief Executive Officer	4,568	0.1870%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALAUNOS THERAPEUTICS, INC.	-0.60%	0.00%	-25.89%	-91.55%	4.24M
WUXI APPTEC CO., LTD.	+1.03%	-2.05%	+39.28%	+94.60%	68.87B
ARGENX SE	+1.31%	+0.55%	+49.48%	+92.12%	65.29B
INSMED INCORPORATED	-0.49%	+3.42%	-12.52%	+376.07%	27.65B
WUXI BIOLOGICS (CAYMAN) INC.	+2.97%	-0.10%	+41.86%	+14.84%	25.77B
BIONTECH SE	-0.49%	-7.26%	+2.88%	-15.32%	26.08B
GENMAB A/S	+1.01%	+1.38%	+26.48%	-17.50%	20.14B
PHARMAESSENTIA CORPORATION	+3.45%	-14.83%	+225.22%	+389.50%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-4.55%	-0.36%	+549.41%	15.03B
EXELIXIS, INC.	+1.76%	+7.67%	+60.98%	+167.18%	14.5B
Average	+1.12%	-2.99%	+40.74%	+155.93%	28.04B
Weighted average by Cap.	+1.15%	-2.12%	+42.77%	+142.22%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.1 0.04 0.48 0.04 0.04 1.56	0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.24 0.02 0.02 0.78
Net income	-4.68M -4.03M -3.78M -3.46M -6.45M -442M -6.5M -44.69M -17.4M -226M -17.57M -17.19M -728M	-4.18M -3.59M -3.37M -3.08M -5.76M -395M -5.8M -39.89M -15.53M -202M -15.68M -15.34M -650M
Net Debt	-1.09M -939K -881K -806K -1.5M -103M -1.52M -10.42M -4.06M -52.7M -4.1M -4.01M -170M	-1.38M -1.19M -1.12M -1.02M -1.91M -131M -1.92M -13.23M -5.15M -66.91M -5.2M -5.09M -215M